T1	p 94 116	diarrhea in children .
T2	p 190 200	children .
T3	p 369 402	acute invasive diarrhea requiring
T4	p 425 442	southern Israel .
T5	p 714 757	diarrhea in infants and children . PATIENTS
T6	p 770 964	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room
T7	p 1194 1215	Shigella , Salmonella
T8	p 1218 1235	Campylobacter spp
T9	p 1458 1472	% ) patients :
T10	p 1483 1495	) Shigella ;
T11	p 1499 1500	(
T12	p 1504 1518	% ) Salmonella
T13	p 1531 1532	)
T14	p 1555 1574	% ) Campylobacter .
T15	p 2423 2488	ambulatory pediatric patients requiring an emergency room visit .
T16	i 6 75	Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment
T17	i 281 320	antibiotics , intramuscular ceftriaxone
T18	i 665 678	ciprofloxacin
T19	i 999 1025	ciprofloxacin suspension (
T20	i 1043 1061	day + im placebo ;
T21	i 1074 1124	im ceftriaxone ( 50 mg/kg/day + placebo suspension
T22	i 1485 1493	Shigella
T23	i 1803 1816	ciprofloxacin
T24	i 1821 1832	ceftriaxone
T25	i 2006 2014	Shigella
T26	i 2110 2123	ciprofloxacin
T27	i 2138 2149	ceftriaxone
T28	i 2293 2311	Oral ciprofloxacin
T29	i 2355 2366	ceftriaxone
T30	o 79 102	acute invasive diarrhea
T31	o 143 151	diarrhea
T32	o 227 258	resistance of enteric pathogens
T33	o 576 584	diarrhea
T34	o 614 633	efficacy and safety
T35	o 714 722	diarrhea
T36	o 1325 1353	Clinical response and safety
T37	o 1430 1443	127 pathogens
T38	o 1575 1608	Overall bacteriologic eradication
T39	o 1738 1766	Clinical cure or improvement
T40	o 1857 1883	Serum ciprofloxacin values
T41	o 2056 2083	drug-related adverse events
T42	o 2184 2213	transient . Joint examination
T43	o 2319 2323	safe
T44	o 2328 2337	effective
T45	o 2383 2433	treatment of acute invasive diarrhea in ambulatory